Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Ruby laser treatment is effective and well-tolerated for reducing hair growth.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Methotrexate plus prednisolone had the fewest serious side effects.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Topical JAK inhibitors may help children with alopecia areata regrow hair.